Cadrenal Therapeutics to Participate in Lytham Partners Fall 2026 Investor Conference

PONTE VEDRA, Fla., Sept. 21, 2026 /CourierPR/ -- Cadrenal Therapeutics, Inc., a late-stage biopharmaceutical company focused on specialized therapies for critical care cardiology and orphan cardiovascular conditions, will participate in the Lytham Partners Fall 2026 Investor Conference, which is taking place virtually from September 29 to 30, 2026.

CEO Quang X. Pham will present at a webcast on Tuesday, September 29, at 10:15 a.m. Eastern Time. The webcast can be accessed via the conference website at lythampartners.com/fall2026 or directly at app.webinar.net/45v0RKgRmKD. The presentation will also be available for replay following the event.

Cadrenal Therapeutics' pipeline includes several promising therapies. CAD-1005, an investigational therapeutic, is in development for the treatment of heparin-induced thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This novel drug is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression. The company has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for prophylaxis of thrombosis in patients with HIT, FDA Fast Track designation for the treatment and prevention of HIT, and an orphan designation from the European Medicines Agency (EMA) for the treatment of platelet-activating factor 4 disorders.

Second-generation 12-LOX oral therapeutics, CAD-2000, are also in development for chronic indications. The company's broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and atrial fibrillation, those with left ventricular assist devices, and potentially those with Kawasaki disease (KD), an acute, self-limited, febrile illness that primarily affects children under 5 years old and is the leading cause of acquired heart disease in developed countries. Tecarfarin has also received Orphan Drug and Fast Track designations from the FDA.